{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:12:06Z","timestamp":1788516726894,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602559"],"award-info":[{"award-number":["81602559"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.critrevonc.2026.105348","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:23:43Z","timestamp":1777674223000},"page":"105348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Precision medicine in bladder cancer: Redefining treatment paradigms through ADCs, immunotherapy, and molecular subtyping"],"prefix":"10.1016","volume":"223","author":[{"given":"Tengyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6284-8993","authenticated-orcid":false,"given":"Yanhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105348_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156074","article-title":"Interactions in hepatic tumor microenvironment: potential targets and modulations for effective therapy","volume":"272","author":"Altalbawy","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.critrevonc.2026.105348_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1266533","article-title":"Describing financial toxicity among cancer patients in different income countries: a systematic review and meta-analysis","volume":"11","author":"Azzani","year":"2024","journal-title":"Front. Public Health"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105348_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105348_bib4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/pharmaceutics17020258","article-title":"Understanding the toxicity profile of approved ADCs","volume":"17","author":"Ballest\u00edn","year":"2025","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105348_bib5","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ccell.2024.02.013","article-title":"Long-lasting mRNA-encoded interleukin-2 restores CD8(+) t cell neoantigen immunity in MHC class i-deficient cancers","volume":"42","author":"Beck","year":"2024","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105348_bib6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.euo.2022.03.008","article-title":"Quality of life data in CheckMate 274: does it move the needle","volume":"5","author":"Bergerot","year":"2022","journal-title":"? Eur. Urol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105348_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008735","article-title":"Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy","volume":"12","author":"Betof Warner","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105348_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40291-023-00647-0","article-title":"Urothelial bladder cancer: genomic alterations in fibroblast growth factor receptor","volume":"27","author":"Bou Zerdan","year":"2023","journal-title":"Mol. Diagn. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105348_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2025.110986","article-title":"Circulating tumor DNA in urothelial cancer as an intermediate disease state between localized and advanced stages: moving from risk factors to micrometastatic disease in the perioperative setting","volume":"44","author":"Bracarda","year":"2026","journal-title":"Urol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105348_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euf.2024.05.011","article-title":"Therapies after progression on enfortumab vedotin and pembrolizumab: navigating second-line options for metastatic urothelial carcinoma in the new treatment landscape","volume":"10","author":"Brown","year":"2024","journal-title":"Eur. Urol. Focus"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105348_bib11","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1535-7163.MCT-22-0013","article-title":"Overcoming resistance to anti-nectin-4 antibody-drug conjugate","volume":"21","author":"Cabaud","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib12","article-title":"Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges","volume":"4","author":"Chen","year":"2025","journal-title":"BMJ Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105348_bib13","first-page":"1532","article-title":"Exploratory analyses of treatment subgroup interaction by PD-l1 status and according to PD-l1 expression in the JAVELIN bladder 100 trial","volume":"26","author":"Climent","year":"2024","journal-title":"Clinical & translational oncology official publication Federation Spanish Oncology Societies National Cancer Institute Mexico"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105348_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3233\/BLC-230071","article-title":"PARP inhibitors for metastatic urothelial carcinoma: a systematic review of efficacy and safety","volume":"9","author":"Crabb","year":"2023","journal-title":"Bladder Cancer (Amsterdam Netherlands)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2024.10.012","article-title":"Unmet need in non-muscle-invasive bladder cancer failing bacillus calmette-gu\u00e9rin therapy: a systematic review and cost-effectiveness analyses from the international bladder cancer group","volume":"8","author":"D'Andrea","year":"2025","journal-title":"Eur. Urol. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105348_bib16","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/bco2.418","article-title":"Role of b7-h3 in predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"5","author":"Deol","year":"2024","journal-title":"BJUI Compass"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105348_bib17","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.3390\/cancers16223753","article-title":"Association of antibody-drug conjugate (ADC) target expression and interstitial lung disease (ILD) in non-small-cell lung cancer (NSCLC): association or causation or neither?","volume":"16","author":"Desai","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105348_bib18","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.3390\/cancers16173056","article-title":"Contemporary molecular markers for predicting systemic treatment response in urothelial bladder cancer: a narrative review","volume":"16","author":"Dimitrov","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105348_bib19","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/curroncol32050278","article-title":"Mechanistic insights and future directions for enfortumab vedotin in urothelial carcinoma: highlights from the 10th annual leo & anne albert institute for bladder cancer care and research symposium","volume":"32","author":"Fahey","year":"2025","journal-title":"Curr. Oncol. (Tor. Ont.)"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105348_bib20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.21037\/tcr-24-1916","article-title":"To be or low TMB (tumor mutational burden","volume":"14","author":"Falk","year":"2025","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105348_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104862","article-title":"Emerging biomarkers in bladder cancer: translating molecular advances into precision oncology","volume":"215","author":"Ferro","year":"2025","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105348_bib22","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1038\/s41591-025-03802-8","article-title":"Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial","volume":"31","author":"Galsky","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.annonc.2025.09.139","article-title":"Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274","volume":"37","author":"Galsky","year":"2026","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102279","article-title":"Evaluation of gemcitabine and carboplatin dosing in patients with cisplatin-ineligible metastatic urothelial carcinoma","volume":"23","author":"Gamvroulas","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105348_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102273","article-title":"Impact of histology on clinical outcomes of pembrolizumab monotherapy in patients with advanced or metastatic urothelial carcinoma in the phase 3 KEYNOTE-045 and KEYNOTE-361 trials","volume":"23","author":"Giannatempo","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib27","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1186\/s12885-021-08085-z","article-title":"Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)","volume":"21","author":"Grivas","year":"2021","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105348_bib28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(25)00158-5","article-title":"Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study","volume":"26","author":"Gupta","year":"2025","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105348_bib29","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/ph14070674","article-title":"Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (ADCs)-a necessity for future ADC research and development","volume":"14","author":"Hammood","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00438-025-02273-3","article-title":"GSK343, an inhibitor of EZH2, prevents acquired cisplatin resistance in bladder cancer","volume":"300","author":"He","year":"2025","journal-title":"Mol. Genet. Genomics MGG"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105348_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.70033","article-title":"Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: a multi-center real-world study","volume":"4","author":"Hu","year":"2025","journal-title":"iMeta"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105348_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/curroncol33020103","article-title":"Predictors of response and mechanisms of resistance to antibody drug conjugates in urothelial carcinoma","volume":"33","author":"Huang","year":"2026","journal-title":"Curr. Oncol. (Tor. Ont.)"},{"key":"10.1016\/j.critrevonc.2026.105348_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1669526","article-title":"Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma","volume":"15","author":"Jaime-Casas","year":"2025","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2026.105348_bib34","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3332\/ecancer.2025.1941","article-title":"Wisely frugal: ensuring sustainable funding for novel cancer therapeutics through a budget impact analysis in resource-limited settings","volume":"19","author":"Joseph","year":"2025","journal-title":"Ecancermedicalscience"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105348_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/bju.16092","article-title":"Drug costs: acquisition costs are critical but not the entire story of financial toxicity","volume":"132","author":"Kaye","year":"2023","journal-title":"BJU Int."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105348_bib36","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105348_bib37","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10147-025-02950-8","article-title":"Pan-asian subgroup analysis of EV-302\/KEYNOTE-a39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma","volume":"31","author":"Kikuchi","year":"2026","journal-title":"Int. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/ijms25010087","article-title":"The relationship between trop-2, chemotherapeutic drugs, and chemoresistance","volume":"25","author":"Koltai","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib39","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.5489\/cuaj.9096","article-title":"2025 canadian urological association expert report: muscle-invasive bladder cancer","volume":"19","author":"Kulkarni","year":"2025","journal-title":"Can. Urol. Assoc. J."},{"key":"10.1016\/j.critrevonc.2026.105348_bib40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2340\/sju.v60.43875","article-title":"Characterization of treatment patterns and outcomes in muscle-invasive bladder cancer patients in sweden","volume":"60","author":"Kwok","year":"2025","journal-title":"Scand. J. Urol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105348_bib41","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1158\/2767-9764.CRC-25-0069","article-title":"Patterns of HER2 expression in metastatic prostate and urothelial cancers: implications for HER2-targeted therapies","volume":"5","author":"Lee","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105348_bib42","article-title":"Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer","volume":"73","author":"Li","year":"2024","journal-title":"Drug Resist. Update. Rev. Comment. Antimicrob. Anticancer Chemother."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105348_bib43","article-title":"Research progress on the combination of PARP inhibitors (PARPi) and immune checkpoint inhibitors (ICIs)","volume":"9","author":"Liu","year":"2025","journal-title":"Adv. Biol. (Weinh.)"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105348_bib44","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105348_bib45","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105348_bib46","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/14712598.2025.2538609","article-title":"A randomized, double blind, parallel design, repeat dose, 2-arm, multicenter study comparing the efficacy, safety, immunogenicity, and pharmacokinetic profiles of a denosumab biosimilar, AVT03, in postmenopausal women with osteoporosis","volume":"25","author":"Lortkipanidze","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105348_bib47","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.eururo.2022.01.032","article-title":"Health-related quality of life of patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin after platinum and PD-1\/PD-l1 inhibitor therapy: results from cohort 1 of the phase 2 EV-201 clinical trial","volume":"81","author":"McGregor","year":"2022","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105348_bib48","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1080\/14737140.2025.2543454","article-title":"Established and emerging biomarkers approaches in urothelial carcinoma","volume":"25","author":"Membribes","year":"2025","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105348_bib49","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ccell.2021.06.011","article-title":"Learning from BISCAY: the future of biomarker-based trial design in bladder cancer","volume":"39","author":"Meza","year":"2021","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105348_bib50","first-page":"1163","article-title":"Releasing the safety CAR","volume":"18","author":"Miura","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1556\/030.2025.02719","article-title":"The impact of gut microbiota modulation on responses to immune checkpoint inhibitors in cancer","volume":"73","author":"Ni","year":"2025","journal-title":"Acta Microbiol. Immunol. Hung."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105348_bib52","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/2326-6066.CIR-22-0326","article-title":"Coexisting alterations of MHC class i antigen presentation and IFN\u03b3 signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy","volume":"10","author":"Nielsen","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105348_bib53","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.eururo.2024.05.014","article-title":"Whole-genome mutational analysis for tumor-informed detection of circulating tumor DNA in patients with urothelial carcinoma","volume":"86","author":"Nordentoft","year":"2024","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105348_bib54","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4111\/icu.20250008","article-title":"Contemporary management of metastatic urothelial carcinoma","volume":"66","author":"Oh","year":"2025","journal-title":"Invest. Clin. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105348_bib55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajur.2024.08.005","article-title":"Bladder preservation alternatives in non-metastatic muscle-invasive bladder tumor: a systematic review and meta-analysis","volume":"12","author":"Parrao","year":"2025","journal-title":"Asian J. Urol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105348_bib56","article-title":"Biological and therapeutic implications of FGFR alterations in urothelial cancer: a systematic review from non-muscle-invasive to metastatic disease","volume":"49","author":"Pichler","year":"2025","journal-title":"Actas Urol. Esp."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105348_bib57","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.urolonc.2025.07.034","article-title":"Liquid biopsy testing in urological cancers: focus on urine","volume":"43","author":"Pisapia","year":"2025","journal-title":"Urol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105348_bib58","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105348_bib59","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41591-021-01317-6","article-title":"An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer","volume":"27","author":"Powles","year":"2021","journal-title":"Nat. Med."},{"issue":"10122","key":"10.1016\/j.critrevonc.2026.105348_bib60","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105348_bib61","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105348_bib62","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105348_bib63","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"28","key":"10.1016\/j.critrevonc.2026.105348_bib64","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1080\/14796694.2025.2579003","article-title":"A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract","volume":"21","author":"Powles","year":"2025","journal-title":"Future Oncol. (Lond. Engl.)"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105348_bib65","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-a39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105348_bib66","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41585-025-01075-x","article-title":"HER2 and urothelial carcinoma: current understanding and future directions","volume":"23","author":"Raggi","year":"2026","journal-title":"Nat. Rev. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105348_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70479","article-title":"Real-life impact of enfortumab vedotin or chemotherapy in the sequential treatment of advanced urothelial carcinoma: the ARON-2 retrospective experience","volume":"14","author":"Rizzo","year":"2025","journal-title":"Cancer Med"},{"issue":"44","key":"10.1016\/j.critrevonc.2026.105348_bib68","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1038\/s41388-020-01465-y","article-title":"EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer","volume":"39","author":"Rose","year":"2020","journal-title":"Oncogene"},{"issue":"10031","key":"10.1016\/j.critrevonc.2026.105348_bib69","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"29","key":"10.1016\/j.critrevonc.2026.105348_bib70","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib71","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s10238-025-01574-6","article-title":"Tumor infiltration therapy: from FDA approval to next-generation approaches","volume":"25","author":"Shaik","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105348_bib72","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.euo.2024.01.013","article-title":"Profiling fibroblast growth factor receptor 3 expression based on the immune microenvironment in upper tract urothelial carcinoma","volume":"7","author":"Shigeta","year":"2024","journal-title":"Eur. Urol. Oncol."},{"issue":"3S","key":"10.1016\/j.critrevonc.2026.105348_bib73","first-page":"S581","article-title":"Tumor-infiltrating lymphocyte therapy for melanoma and other solid tumors: looking back, yet moving forward","volume":"31","author":"Shoushtari","year":"2025","journal-title":"Transpl. Cell Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105348_bib74","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105348_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2022.12.019","article-title":"Management of fibroblast growth factor inhibitor treatment-emergent adverse events of interest in patients with locally advanced or metastatic urothelial carcinoma","volume":"50","author":"Siefker-Radtke","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105348_bib76","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/14796694.2025.2482363","article-title":"Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer","volume":"21","author":"Sternschuss","year":"2025","journal-title":"Future Oncol. (Lond. Engl.)"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105348_bib77","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105348_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105039","article-title":"Unlocking precision: bispecific t cell engagers and the next frontier in uro-oncology","volume":"217","author":"Tan","year":"2026","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib79","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35590","article-title":"Global disparities in cancer care: bridging the gap in affordability and access to medications between high and low-income countries","volume":"131","author":"Tfayli","year":"2025","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105348_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105544","article-title":"Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma","volume":"10","author":"van der Heijden","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib81","first-page":"14","article-title":"Trop-2 protein as a therapeutic target: a focused review on trop-2-based antibody-drug conjugates and their predictive biomarkers","volume":"22","author":"Vranic","year":"2022","journal-title":"Bosn. J. Basic Med. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105348_bib82","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of PD-(l)1 blockade efficacy in cancer: challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105348_bib83","article-title":"Targeting 4-1BB and PD-l1 induces potent and durable antitumor immunity in b-cell lymphoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105348_bib84","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/03915603251347444","article-title":"Comparison of long-term survival for muscle-invasive bladder cancer patients who underwent bladder preservation therapy and radical cystectomy: a systematic review and meta-analysis","volume":"92","author":"Warli","year":"2025","journal-title":"Urologia"},{"key":"10.1016\/j.critrevonc.2026.105348_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104767","article-title":"The interplay between gut microbiota, antibiotics, and immune checkpoint inhibitors in patients with cancer: a narrative review with biological and clinical aspects","volume":"212","author":"Wekking","year":"2025","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib86","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jacr.2022.09.036","article-title":"Financial toxicity in the post-health reform era","volume":"20","author":"Wu","year":"2023","journal-title":"J. Am. Coll. Radio."},{"key":"10.1016\/j.critrevonc.2026.105348_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1670574","article-title":"Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy","volume":"15","author":"Xiang","year":"2025","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105348_bib88","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011881","article-title":"Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48","volume":"13","author":"Xiao","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105348_bib89","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251357527","article-title":"First-line systemic therapy in patients with metastatic or locally advanced urothelial carcinoma: a systematic review and network meta-analysis of randomized controlled trials","volume":"17","author":"Xie","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105348_bib90","article-title":"Perineural invasion and the \"cold\" tumor microenvironment in pancreatic cancer: mechanisms of crosstalk and therapeutic opportunities","volume":"16","author":"Xu","year":"2025","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105348_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/bco2.70031","article-title":"Novel neoadjuvant therapies for muscle-invasive bladder cancer: systematic review and meta-analysis","volume":"6","author":"Yajima","year":"2025","journal-title":"BJUI Compass"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105348_bib92","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105348_bib93","doi-asserted-by":"crossref","first-page":"15304","DOI":"10.1002\/cam4.6175","article-title":"Mutational pattern off homologous recombination repair (HRR)-related genes in upper tract urothelial carcinoma","volume":"12","author":"Yang","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105348_bib94","first-page":"63","article-title":"Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies","volume":"8","author":"Zhao","year":"2025","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib95","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","article-title":"Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105348_bib96","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-c014): a phase ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105348_bib97","first-page":"64","article-title":"Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021","volume":"11","author":"Zi","year":"2024","journal-title":"Mil. Med. Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:56:50Z","timestamp":1783144610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":97,"alternative-id":["S1040842826002350"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105348","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision medicine in bladder cancer: Redefining treatment paradigms through ADCs, immunotherapy, and molecular subtyping","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105348"}}